Anti-Infectives · LP-030
Chloramphenicol Eye drops
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-030Anti-Infectives
- Generic identity
- ChloramphenicolEye drops
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-030
- Generic identity
- Chloramphenicol
- Presentation
- Eye drops
- Catalogue strength
- 0.5%
- Catalogue pack
- Dropper bottle 5 mL / 10 mL
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: chloramphenicol.
- Dosage form/route: eye drops.
- Catalogue concentration: 0.5%.
- Catalogue dropper-bottle options: 5 mL and 10 mL.
Layer 02 · Unresolved product-specific fields
- Sterile formulation, preservative system, pH/osmolality and exact chloramphenicol basis.
- Dropper/container-closure performance and whether product is multidose or another specific presentation.
- Approved ocular indication, age eligibility, contact-lens instructions and in-use discard period.
- Pack/SKU status, storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 0.5% | Eye drops | — | Dropper bottle 5 mL | Sterility/formula/container and in-use evidence not supplied. |
| B | 0.5% | Eye drops | — | Dropper bottle 10 mL | Sterility/formula/container and in-use evidence not supplied. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Chloramphenicol is an antibiotic that is used in specific ophthalmic formulations for selected bacterial eye infections. Eye drops and eye ointment have different handling and transient effects on vision. A red or irritated eye does not by itself establish a bacterial diagnosis. This page concerns general ophthalmic ingredient education and does not establish a Luang Pharma approved indication, sterility specification or suitability for a particular age.
Clinical context and therapeutic role
Professional assessment should distinguish uncomplicated surface infection from corneal disease, trauma, allergy or viral infection. Eye pain, light sensitivity, reduced vision or symptoms in a contact-lens wearer may require prompt specialist assessment. An ophthalmic antibiotic is not appropriate for every red eye. Relevant history includes previous reactions to chloramphenicol and blood disorders, while the selected product’s age restrictions and precise site of use must be checked.
Selected safety context
Temporary stinging, irritation or blurred vision may occur, especially with ointment. Allergy and rare serious blood disorders are important considerations; prior blood problems or a personal or family history relevant to chloramphenicol needs review. Do not share eye products or contaminate the applicator tip. A painful red eye, visual loss, persistent symptoms or marked swelling requires urgent assessment. Contact lens use should follow professional advice and the exact product leaflet.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue identifies an ophthalmic liquid presentation. Ophthalmic suitability, sterility, preservative content, container design and the approved route must be confirmed for the actual product. A percentage strength alone does not establish interchangeability with ear drops, skin solutions or another eye-drop formulation.
Follow hand-hygiene and applicator instructions, avoiding contact between the dropper tip and the eye or other surfaces. Keep the bottle labeled and do not share it. The in-use period, storage conditions and handling after opening are specific to the supplied product.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Sterile finished-product specification and quantitative formula.
Approved ophthalmic label/leaflet with in-use/contact-lens instructions.
Dropper/container-closure specification and size-to-SKU matrix.
Registration/market-status and manufacturing-site evidence for each exact sterile presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: About chloramphenicolArchived source classification: public-health route-specific medicine reference | Source revision recorded: Page reviewed 30 January 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-030.
Professional enquiries
Request product-specific evidence for LP-030.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.